MIM
PALI icon

MetLife Investment Management’s Palisade Bio PALI Stock Holding History

MetLife Investment Management’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$184K Buy
+87,875
New +$173K ﹤0.01% 2461

Other funds holding PALI

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

MetLife Investment Management's PALI Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Palisade Bio (PALI) in Q2 2026: 87,875 shares worth $184K. The stake represents ﹤0.01% of the portfolio and ranks #2461 among its holdings.

124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

  • MetLife Investment Management held 87,875 shares of Palisade Bio worth $184K as of Q2 2026.
  • Palisade Bio was a new MetLife Investment Management position in Q2 2026.
  • Palisade Bio made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2461 holding.
  • 124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.